Ever since generic DAA made available in early 2015 with Gilead’s VL to several Indian generic manufacturers, there has been some progress as well as challenges in the context of access to Hepatitis C treatment. During Asia Pacific AIDS and Co-infection conference in Hong Kong June 2017, Giten Khwahirakpam from TREATAsia presented the latest updates on treatment access in the region. The presentation includes information on availability, pricing and regulatory of generic DAAs. Please click here to see highlighted powerpoint slides. You can also watch the full presentation session here.